ARS to Present Data from Intranasal Epinephrine (ARS-1) Studies at AAAAI 2020 Annual Meeting
Neffy™ (formally ARS-1) was fast-tracked by the FDA in 2019 as an intranasal alternative to epinephrine auto-injectors.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
